Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2018

View Archived Issues

Exosomes deliver no-NO arginase in diabetes

Novel TZD CMHX-008 maintains insulin sensitization with minor effects on weight gain and bone loss

Feeding findings may hold key to appetite control

Achillion initiates first-in-human study of ACH-5548

Researchers develop a rat model of diabetic cardiomyopathy for cardiovascular evaluation

FDA clears IND for Adagene's phase I study of ADG-106

Investigating isoflavonoids for the potential treatment of obesity and diabetes

[225Ac]DOTA-PEG7-5B1 as pretargeted radioimmunotherapy for pancreatic ductal adenocarcinoma

BioSight receives clearance to initiate phase IIb study of BST-236 in AML

Ovid Therapeutics initiates phase II ROCKET trial of OV-101 in fragile X syndrome

Tegsedi approved in the E.U. for the treatment of hATTR

First patient dosed in phase II study of CV-301 plus nivolumab in metastatic colorectal cancer

Recursion set to begin phase I study of AI/ML-based drug candidate, REC-994

Advaxis withdraws conditional MAA for axalimogene filolisbac, advances ADXS-HOT program

Argenx presents phase II data for ARGX-113 in myasthenia gravis

OG-716, a lantibiotic that is active against Clostridium difficile infections

Amgen describes new beta-secretase inhibitors

National Center for Global Health and Medicine, Kumamoto University and Yamasa patent antivirals

Galapagos, AbbVie discover CFTR modulators

Pivotal study of KP-415 in children with ADHD meets primary efficacy endpoint

New phase II trial explores voclosporin ophthalmic solution for dry eye syndrome

Genmab and Immatics partner on next-generation bispecific cancer immunotherapies

New phase III trial investigates etripamil for termination of spontaneous PSVT

TAS-114 combined with S-1 shows preliminary efficacy in pretreated advanced gastric cancer patients

Japanese researchers present phase II data on TAS-205 in patients with DMD

Phase III maintenance trial of Ninlaro in multiple myeloma meets primary endpoint

Phase III study of Imbruvica in treatment-naive DLBCL misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...